Report cover image

Anti-Obesity Medication Market Size, Share, By Drug Type, Mechanism of Action, Distribution Channel, and Region - Trends, Analysis and Forecast till 2035

Publisher Prophecy Market Insights
Published Dec 01, 2024
Length 187 Pages
SKU # PRMI19511716

Description

Anti-obesity medication, also known as weight loss medications, are pharmacological agents that reduce or control excess body fat. Target market is driven by the increasing cases of obesity, rising awareness of the health consequences associated with being overweight. In addition, rising R&D activities for development of anti-obesity drugs, and increasing investment in R&D sectors are another factors propelling growth of the global market.

Anti-Obesity Medication Market Report Highlights:
  • The anti-obesity medication market size is expected to grow at USD 105.3 billion by 2035.
  • The target market was worth USD 8.5 billion in 2024.
  • Target market is expanding at a CAGR of 31.8%.
  • North America held the largest share of the market in 2024.
  • Asia Pacific is projected to be the fastest-growing market in the coming years.
  • On the basis of drug type, the market is being dominated by the prescription drugs segment.
  • Based on mechanism of action, the centrally acting drugs holds the largest anti-obesity medication market share.
  • Distribution channel, the hospital pharmacies segment is leading the market.
Key Highlights:
  • In November 2024, a recent study published in the JAMA Network Open, researchers evaluated changes in alcohol use among individuals enrolled in a telehealth weight management program after initiating antiobesity medication (AOM). AOMs, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), are effective for achieving significant weight loss. Notably, GLP-1 RAs have also been linked to reduced incidence and recurrence of alcohol use disorder, thus suggesting potential dual benefits of these medications.
  • In November 2024, The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment. The new rule, which was proposed by the administration, would dramatically expand access to anti-obesity medications, such as Ozempic and Wegovy, from Novo Nordisk, and Mounjaro and Zepbound, from Eli Lilly.
Browse ∼40 market data tables and ∼38 figures through ∼183 slides and in-depth TOC on “Anti-Obesity Medication Market Size, Share, By Drug Type, Mechanism of Action, Distribution Channel, and Region - Trends, Analysis, and Forecast till 2035”

Anti-Obesity Medication Market Competitive Landscape:

The key players in the anti-obesity medication market are Novo Nordisk A/S, ELI LILLY AND COMPANY, GSK plc., Currax Pharmaceuticals LLC, Pfizer Inc., Boehringer Ingelheim International GmbH, KVK Tech, Inc., CHEPLAPHARM ARZNEIMITTEL GMBH, Gelesis, VIVUS LLC, Rhythm Pharmaceuticals, Inc., Lupin Ltd., Zydus Group, and BIOCON.

Segmentation:

By Drug Type:
  • Prescription Drugs
  • Over-the-Counter (OTC) Drugs
By Mechanism of Action:
  • Centrally Acting Drugs
  • Peripherally Acting Drugs
By Distribution Channel:
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
By Region:
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

187 Pages
Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
Market Preview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Mechanism of Action
Market Snippet, By Distribution Channel
Market Snippet, By Region
Opportunity Map Analysis
Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Market Trends
Product Launch
Merger and Acquisitions
Impact Analysis
PEST Analysis
Porter’s Analysis
Anti-Obesity Drugs for Long Term Use
Clinical Efficiency
Initiating & Terminating Pharmacotherapy for Obesity
Summary of Warnings & Contraindications
New Product Launches
Latest Technological Advancements
Merger, Acquisitions, and Partnerships
Market Segmentation, By Drug Type, Forecast Period up to 10 Years, (USD Bn)
Overview
Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
Segment Trends
Prescription Drugs
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Over-the-Counter (OTC) Drugs
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Market Segmentation, By Mechanism of Action, Forecast Period up to 10 Years, (USD Bn)
Overview
Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
Segment Trends
Centrally Acting Drugs
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Peripherally Acting Drugs
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Market Segmentation, By Distribution Channel, Forecast Period up to 10 Years, (USD Bn)
Overview
Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
Segment Trends
Retail Pharmacies
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Hospital Pharmacies
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Others
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Market Segmentation, By Region, Forecast Period up to 10 Years, (USD Bn)
Overview
Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
Regional Trends
North America
Market Size and Forecast (USD Bn), By Drug Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Mechanism of Action, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
U.S.
Canada
Asia Pacific
Market Size and Forecast (USD Bn), By Drug Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Mechanism of Action, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
China
India
Japan
Australia
Indonesia
Malaysia
South Korea
Rest of Asia Pacific
Europe
Market Size and Forecast (USD Bn), By Drug Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Mechanism of Action, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
Germany
U.K.
France
Russia
Italy
Spain
Netherlands
Rest of Europe
Latin America
Market Size and Forecast (USD Bn), By Drug Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Mechanism of Action, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
Brazil
Mexico
Argentina
Rest of Latin America
Middle East and Africa
Market Size and Forecast (USD Bn), By Drug Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Mechanism of Action, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
GCC
Israel
South Africa
Rest of Middle East and Africa
Competitive Landscape
Heat Map Analysis
Company Profiles
Novo Nordisk A/S
ELI LILLY AND COMPANY
GSK plc.
Currax Pharmaceuticals LLC
Pfizer Inc.
Boehringer Ingelheim International GmbH
KVK Tech, Inc.
CHEPLAPHARM ARZNEIMITTEL GMBH.
Gelesis
VIVUS LLC
Rhythm Pharmaceuticals, Inc.
Lupin Ltd.
Zydus Group
BIOCON

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us